Form 8-K - Current report:
SEC Accession No. 0001493152-25-010282
Filing Date
2025-03-14
Accepted
2025-03-14 10:25:08
Documents
18
Period of Report
2025-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45448
2 ex10-1.htm EX-10.1 2725
3 ex10-1_001.jpg GRAPHIC 467136
4 ex10-1_002.jpg GRAPHIC 230659
5 ex10-1_003.jpg GRAPHIC 133039
  Complete submission text file 0001493152-25-010282.txt   1417234

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20250311.xsd EX-101.SCH 3785
7 XBRL DEFINITION FILE lixt-20250311_def.xml EX-101.DEF 30058
8 XBRL LABEL FILE lixt-20250311_lab.xml EX-101.LAB 36769
9 XBRL PRESENTATION FILE lixt-20250311_pre.xml EX-101.PRE 27081
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5790
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25738156
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)